Lucy Goods, IncWinter 2018Active☆Watch⊞Compare

Lucy Goods, Inc is one of 233 Biotech companies tracked from Los Angeles, CA, USA, on record since 2017. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Lucy’s mission is to reduce tobacco-related harm to zero. We provide…

If it isn’t bad enough that smokers don’t realize the scientific facts about nicotine, most non-tobacco nicotine products are poorly designed and unappealing to use. The leading gum is sold like a pharmaceutical drug, with flavoring and packaging to match. Vapes provide a cumbersome, over-the-top experience — with use as tightly restricted as cigarette smoking itself, but more juvenile, conspicuous, and highly addictive. People want, and deserve, a better way. Therefore, we want to deliver nicotine users a superior experience, and at the same time give them a way to transition out of feeling dependent. In a better society, people wouldn’t carry around the sensation that they’re stuck with an involuntary habit. Our mission isn’t to encourage nicotine use among people who haven’t started. Unlike certain vapes or other products, ours isn’t the sort coveted by underage users on social media. Our mission is to alleviate the harm related to tobacco — first and foremost, by switching people away from the most harmful products. So, at Lucy, we take an evidence based view of nicotine. Nicotine’s pleasurable properties make it an inevitable part of modern society. Therefore, minimizing harm in all nicotine products is key, in addition to giving people products and strategies for cessation. We feel that, as 1,300 people are dying of tobacco related illnesses every day in the US, the most important and immediate step toward a better society is giving nicotine consumers products they enjoy using that will cause less harm. Our first product is designed to appeal to smokers and encourage them to switch. And, looking ahead, we hope to secure approval in the future as a clinically proven smoking cessation aid, while continuing to participate in the FDA’s public hearings around how NRTs are best regulated. Our goals are simple: because harm reduction is a better strategy around nicotine delivery than abstinence or prohibition, we want to help improve public health — and reduce its costs — through a superior pure nicotine product.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Lucy Goods, Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Lucy Goods, Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Lucy Goods, Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.